Breast Cancer Clinical Trials

• Has Stage II or III histologically confirmed invasive breast carcinoma.

• Has histologically confirmed HER2-positive breast cancer

• Has a known hormone receptor (HR) status of the primary tumor

• Participants with multifocal or multicentric disease are eligible if the largest tumor (which must be larger than or equal to 2 cm in diameter) is HER2-positive, and the treating physician has determined the participant should be treated as HER2-positive.

• Agrees to undergo a mastectomy or breast conserving surgery (BCS) after neoadjuvant therapy.

• Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

• Adequate organ function

• Has an LVEF ≥ 50% as determined by either ECHO or MUGA obtained within 4 weeks prior to first dose of study intervention.

• Adequate contraceptive precautions